$SNOA

Sonoma Pharmaceuticals, Inc. (SNOA) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. Our annual meeting of stockholders was held on September 16, 2026. Proxies were solicited pursuant to our definitive proxy statement filed on July 28, 2026 with the Securities and Exchange Commission under Section 14

Sonoma Pharmaceuticals, Inc. (SNOA) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. On August 19, 2026, Sonoma Pharmaceuticals, Inc. (the “Company”) held an adjourned special meeting of stockholders (the “Special Meeting”), pursuant to a definitive proxy statement, filed with the Securities and Exch

Sonoma Pharmaceuticals reported first-quarter revenue of $6.4 million, up from $4.0 million a year earlier, with U.S. sales up 141% to drive growth. Gross profit rose to $2.6 million (40% margin). EBITDA turned positive at $0.1 million versus a $1.0 million loss. Cash was $5.3 million as of June 30, 2026. Shares rose to $1.24 premarket.

Sonoma Pharmaceuticals (Nasdaq:SNOA) reported fourth-quarter FY2026 results for the quarter ended March 31, 2026. Revenue rose to $5.6M (+48%) from $3.8M; gross profit was $2.2M (39%). Net loss was $0.6M, and EBITDA loss improved 66% to $0.2M. For FY2026, revenue increased to $19.5M (+$5.2M) and EBITDA loss fell 38% to $2.1M. Cash was $2.4M.

Sonoma Pharmaceuticals has closed a public unit offering, raising approximately $3.5 million in net proceeds after expenses. The offering included units of common stock or pre-funded warrants, complemented by common stock purchase warrants, with each unit priced at $1.35. The funds are earmarked for general corporate purposes and working capital.

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Sonoma Pharmaceuticals (SNOA) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Sonoma Pharmaceuticals (SNOA) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.